Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis”

2011 ◽  
Vol 6 (6) ◽  
pp. 581-582
Author(s):  
Rosanna Tarricone
2017 ◽  
Vol 13 ◽  
pp. 61-66 ◽  
Author(s):  
Roza Ismailovna Yagudina ◽  
Andrey Urievich Kulikov ◽  
Vjacheslav Gennadievich Serpik ◽  
Dzhumber Tengizovich Ugrekhelidze

Author(s):  
Marina Ivanovna Soyher ◽  
O. R Orlova ◽  
M. G Soyher ◽  
L. R Mingazova ◽  
E. M Soyher ◽  
...  

Describes a clinical and economic evaluation of the use of botulinum neuroprotein in comparison with standard therapy (muscle relaxants and splint- frames) for a period of 4 months. Cost-effectiveness analysis (CER) is a frequently used method of pharmacoeconomic analysis. Its major parts are cost analysis, effectiveness analysis and results estimation. Undertaking of each part effects the certainty of the final results. Correct estimation of cost-effectiveness analysis makes it possible to increase health care economical resources distribution effectiveness and shows the most effective and respectable treatment instruments. This issue reviews all parts of cost-effectiveness analysis and algorithms of decision making during results estimation


Sign in / Sign up

Export Citation Format

Share Document